1Smith SC Jr,Dove JT,Jaeobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines )-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines [J]. Circulation, 2001, 103 (24) : 3019-3041.
3Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study[J]. J Am Coll Cardiol, 2005,46(10) ; 1820-1826.
4Muller I,Besta F,Schulz C,et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement[J]. Thromb Haemost,2003,89 (5):783-787.
5Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with elopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J].Lancet, 2001,358(9281) : 527-533.
6Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following pereutaneous coronary intervention; a randomized controlled trial [J]. JAMA, 2002,288 (19) : 2411-2420.
7Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test for assessment of individual time-dependent dotting responses to aspirin and elopidogrel using modified thrombelastography[J]. Platelets, 2007,18(7) :497-505.
8Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention:is the current antiplatelet therapy adequate?[J]. J Am Coll Cardiol,2007,49(6):657-666.
9Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines:clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation[J].Catheter Cardiovasc Interv, 2003,59 (3) : 295-302.
10Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J]. Circulation, 2004,109(25): 3171-3175.
5Michelle M. Graham Outcomes of aider-hours versus regular working hours primary percutaneous coronary intervention for acute myocar- dial infarction [J]. BMJ Qual Saf Health Care, 2011,20(1): 60-67.
6Aronow HD. Bleeding risk associated with lyear of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial [J]. Am Heart J, 2009,157(2):369-374.
7Jeong YH, Lee SW, Choi BR. Randomized comparison of adjunetive cilost azol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J Am Coil Cardiol,2009,53: 1101-1109.
8Hwang SJ, Jeong YH, Kim IS, et al. Cytoehr ome 2C19 polymorphism and responseto adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv, 2010,3 : 450-459.
9Aronow WS. Drag treatment of peripheral arterial disease in the elderly. Drugs Aging,2006,23 : 1-12.
10Ochiai M, Isshiki T, Takeshita S, et al. RACTS: a prospective randomized antiplatel et trial of cilostazolversus ticlopidine in patients undergoing coronary stenting: long-term cl inical and angiographic outcome. J Cardiovasc Pharmacol,2005,46:162- 166.
